2010
DOI: 10.1200/jco.2009.23.0342
|View full text |Cite
|
Sign up to set email alerts
|

Single Nucleotide Polymorphism in the Mutational Hotspot of WT1 Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia

Abstract: WT1 SNP rs16754 may be a novel independent favorable-risk marker in CN-AML patients that might improve risk and treatment stratification.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

6
101
4

Year Published

2010
2010
2023
2023

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 116 publications
(111 citation statements)
references
References 45 publications
6
101
4
Order By: Relevance
“…In the subgroup of cytogenetically normal AML, additional mutation analyses were performed for CEBPA 23 and WT1. 24 BAALC, 25 ERG, 26 MN1, 27,28 MLL5 29 and WT1 24 expression levels were quantified as previously described using cDNA from the KG1A cell line (BAALC, ERG and MLL5) or plasmids (MN1 30 and WT1 24 ) to construct a standard curve. 31 …”
Section: Cytogenetic and Molecular Analysismentioning
confidence: 99%
See 1 more Smart Citation
“…In the subgroup of cytogenetically normal AML, additional mutation analyses were performed for CEBPA 23 and WT1. 24 BAALC, 25 ERG, 26 MN1, 27,28 MLL5 29 and WT1 24 expression levels were quantified as previously described using cDNA from the KG1A cell line (BAALC, ERG and MLL5) or plasmids (MN1 30 and WT1 24 ) to construct a standard curve. 31 …”
Section: Cytogenetic and Molecular Analysismentioning
confidence: 99%
“…20,24 Genomic and mitochondrial DNA were extracted from samples using the All Prep DNA/RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. Complete coverage of the mitochondrial ND4 gene sequence was accomplished using three overlapping PCR.…”
Section: Analysis Of Nd4 Mutationsmentioning
confidence: 99%
“…Recently, WT1 SNP rs16754 was suggested to predict favorable clinical outcome in adults with cytogenetically normal (CN) AML. 2 Conflicting data on the prognostic impact of this SNP have subsequently been reported in pediatric AML. 3,4 In our study, we assessed the prevalence, the main associated features and the prognostic significance of WT1 SNP rs16754 in a large cohort of adult AML patients.…”
mentioning
confidence: 99%
“…These frequencies are similar to those previously observed in AML patients and in controls. [2][3][4] Comparisons of clinical and biological characteristics of patients were performed according to WT1 SNP rs16754 status. In our cohort, patients with at least one minor allele were found to be older than patients with two major alleles (median age: 54 vs 49 years, P ¼ 0.006).…”
mentioning
confidence: 99%
“…All 109 patients were enrolled on the AML SHG 0199 trail (ClinicalTrials Identifier NCT00209833). All patients received intensive, response-adapted double induction and consolidation therapy as previously described 6,7 . Alteration of the nucleotide at position 106 with a G to A 3 substitution (G106A) was found in 15% (16 of 109) of the patients ( Figure 1A).…”
Section: To the Editormentioning
confidence: 99%